**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 45-year-old man developed bradycardia and atrioventricular block during off-label treatment with lopinavir/ritonavir for COVID-19 pneumonia. Additionally, azithromycin (empiric treatment) and dexmedetomidine contributed to the bradycardia \[*not all indications, dosages, routes and outcomes stated*\].

The man was hospitalised to the ICU due to severe pneumonia and respiratory failure since ten days. His medical history was significant for asthma, hypertension and diabetes mellitus, which was under control. He had been receiving dexmedetomidine therapy. Due to the suspicion of COVID-19 pneumonia, he was kept in an isolated room under droplet and contact precaution with additional airborne protection. After the hospitalisation, he was kept on lung-protective mechanical ventilation and neuromuscular blockade was initiated under sedation. Later, he was administered empirical treatment with azithromycin 500mg every 24h, ceftriaxone and peramivir. However, his oxygenation gradually worsened 24h later. On day 2 of the admission, he vancomycin was added. Due to inadequate treatment for respiratory failure, he underwent venovenous extracorporeal membrane oxygenation (VV-ECMO) under heparin anticoagulation therapy. On day 4 of the admission, he was diagnosed with COVID-19 pneumonia, was treated with off-label lopinavir/ritonavir 400/100mg two tablets twice a day via nasogastric tube for 14 days. After two days of lopinavir/ritonavir initiation, he developed bradycardia with atrioventricular block as side effects of lopinavir/ritonavir. Also, azithromycin and dexmedetomidine contributed to the bradycardia \[*not all duration of treatments to reaction onsets stated*\].

The man\'s dexmedetomidine and azithromycin treatment was stopped. No further intervention was required. On day 6 of the admission, he underwent tracheostomy and was removed from the ventilator. An improvement in the lung compliance was noted. On day 12 of the admission, decannulation and removal of VV-ECMO was performed, and he was started on meropenem. After day 14 and day 18, the mechanical ventilation and oxygen supports were removed. His PCR tests were negative on day 13 and day 15. On day 24, he was discharged.
